中卟啉Ⅸ | 493-90-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 四吡咯及其衍生物
• 中文名称: 中卟啉Ⅸ
• 英文名称: Mesoporphyrin IX
• 英文别名: 3-[18-(2-carboxyethyl)-8,13-diethyl-3,7,12,17-tetramethyl-22,23-dihydroporphyrin-2-yl]propanoic acid
• CAS: 493-90-3
• 化学式: C₃₄H₃₈N₄O₄
• 分子量: 566.7
• InChiKey: NCAJWYASAWUEBY-UHFFFAOYSA-N

物化性质

• 沸点：
  1096.1±65.0 °C(Predicted)
• 密度：
  1.240±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  42
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  132
• 氢给体数：
  4
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  Mesoporphyrin ix dimethyl ester 以 ammonium hydroxide 为溶剂， 生成 中卟啉Ⅸ
  参考文献：
  名称：

  Methods for synthesizing metal mesoporphyrins

  摘要：

  实施例描述了合成金属中间体卟啉化合物的方法。在实施例中，可以通过血红素转金属化和随后的氢化锡原卟啉IX来形成金属中间体卟啉化合物。在其他实施例中，合成金属中间体卟啉化合物的方法包括从血红素形成原卟啉甲酯，然后通过金属插入和氢化将原卟啉甲酯中间体转化为金属中间体卟啉化合物。在其他实施例中，可以通过无氢氢化方法从血红素形成mesoporphyrin IX中间体，随后进行金属插入和氢化来形成金属中间体卟啉化合物。在实施例中，合成金属中间体卟啉化合物的方法包括形成mesoporphyrin IX二盐酸盐中间体化合物，并通过金属插入将mesoporphyrin IX中间体转化为金属中间体卟啉化合物。在实施例中，可以直接从血红素形成金属中间体卟啉化合物，而无需隔离任何中间体。

  公开号：

  US09181285B2

文献信息

• METHODS FOR SYNTHESIZING METAL MESOPORPHYRINS
  申请人：INFACARE PHARMACEUTICAL CORPORATION

  公开号：US20140228560A1

  公开（公告）日：2014-08-14

  Embodiments describe methods of synthesizing metal mesoporphyrin compounds. In embodiments, a metal mesoporphyrin compound may be formed by hemin transmetallation and subsequent hydrogenation of the tin protoporphyrin IX to form a metal mesoporphyrin. In other embodiments, a method of synthesizing a metal mesoporphyrin compound comprises forming a protoporphyrin methyl ester from hemin and converting the protoporphyrin methyl ester intermediate to a metal mesoporphyrin compound through metal insertion and hydrogenation. In other embodiments, a metal mesoporphyrin compound may be formed from hemin by a hydrogen-free hydrogenation method to form a mesoporphyrin IX intermediate followed by metal insertion and hydrogenation. In embodiments, a method of synthesizing a metal mesoporphyrin compound comprises forming a mesoporphyrin IX dihydrochloride intermediate compound and converting the mesoporphyrin IX intermediate to a metal mesoporphyrin compound through metal insertion. In embodiments, a metal mesoporphyrin compound may be formed directly from hemin without isolation of any intermediates.

  实施例描述了合成金属介孔卟啉化合物的方法。在实施例中，金属介孔卟啉化合物可以通过血红素跨金属和随后的氢化锡原卟啉IX形成金属介孔卟啉。在其他实施例中，合成金属介孔卟啉化合物的方法包括从血红素形成原卟啉甲酯，通过金属插入和氢化将原卟啉甲酯中间体转化为金属介孔卟啉化合物。在其他实施例中，金属介孔卟啉化合物可以通过无氢氢化方法从血红素形成介孔卟啉IX中间体，然后进行金属插入和氢化来形成。在实施例中，合成金属介孔卟啉化合物的方法包括形成介孔卟啉IX二盐酸盐中间化合物，并通过金属插入将介孔卟啉IX中间体转化为金属介孔卟啉化合物。在实施例中，金属介孔卟啉化合物可以直接从血红素形成，无需隔离任何中间体。
• FORMULATIONS AND USES FOR MICROPARTICLE DELIVERY OF METALLOPORPHYRINS
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：US20170035778A1

  公开（公告）日：2017-02-09

  Formulations and methods of use thereof that relate to biocompatible delivery of stabilized porphyrin complexes are provided. Formulations may include microparticles comprising the porphyrin complex, wherein the porphyrin active agent is admixed or coated with a pharmaceutically acceptable stabilizer.
• [EN] METALLOPORPHYRIN MICROPARTICLES FOR TREATMENT OF ANEMIA AND TROPICAL DISEASES<br/>[FR] MICROPARTICULES DE MÉTALLOPORPHYRINES POUR LE TRAITEMENT DE L'ANÉMIE ET DE MALADIES TROPICALES
  申请人：UNIV LELAND STANFORD JUNIOR

  公开号：WO2018144845A1

  公开（公告）日：2018-08-09

  Methods of use for reducing the serum iron concentration to treatment of various conditions using a composition comprising microparticles comprising a metal porphyrin complex and a pharmaceutically acceptable stabilizer are disclosed.
• [EN] COMPOSITIONS AND THEIR USES FOR TREATING CANCERS<br/>[FR] COMPOSITIONS ET LEURS UTILISATIONS POUR LE TRAITEMENT DE CANCERS
  申请人：INST NAT SANTE RECH MED

  公开号：WO2021105761A1

  公开（公告）日：2021-06-03

  The present invention relates to the field of oncology, and in particular to chemoresistant or potentially chemoresistant cancer diseases. The invention relates to a combination comprising at least one anticancer G-quadruplex ligand (G4 ligand), such as triarylpyridine 20A or quarfloxin, and at least one lysosomotropic agent, such as chloroquine or Lys05. Such combinations promote a significant induction of lysosomal membrane permeabilization (LMP) as compared to a single drug treatment and trigger massive cancer cell death. The observed synergistic effect has advantageous application in the prevention and/or treatment of chemoresistant cancer.